Cryptotanshinone, an orally bioactive herbal compound from Danshen, attenuates atherosclerosis in apolipoprotein E-deficient mice: Role of lectin-like oxidized LDL receptor-1 (LOX-1)

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5661-5675

  Liu, Zhiping ^a,b   Xu, Suowen ^a,c   Huang, Xiaoyang ^a   Wang, Jiaojiao ^a   Gao, Si ^a   Li, Hong ^a   Zhou, Changhua ^a   Ye, Jiantao ^a   Chen, Shaorui ^a   Jin, Zheng Gen ^c   Liu, Peiqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CRYPTOTANSHINONE; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; HERBACEOUS AGENT; OLR1 PROTEIN, MOUSE; PHENANTHRENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DEFICIENCY; DOSE RESPONSE; FEMALE; GENETICS; ISOLATION AND PURIFICATION; KNOCKOUT MOUSE; METABOLISM; ORAL DRUG ADMINISTRATION; PHYTOTHERAPY; SALVIA MILTIORRHIZA; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENANTHRENES; PHYTOTHERAPY; REACTIVE OXYGEN SPECIES; SALVIA MILTIORRHIZA; SCAVENGER RECEPTORS, CLASS E; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84949537809     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13068     Document Type: Article

References (63)

1. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, et al. (2004). Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109: 227-233.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol. 170: 1652-1675.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol. 170: 1797-1867.
4. Ang KP, Tan HK, Selvaraja M, Kadir AA, Somchit MN, Akim AM, et al. (2011). Cryptotanshinone attenuates in vitro oxLDL-induced pre-lesional atherosclerotic events. Planta Med 77: 1782-1787.
5. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, et al. (2011). Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 121: 2693-2708.
6. Chen W, Luo Y, Liu L, Zhou H, Xu B, Han X, et al. (2010). Cryptotanshinone inhibits cancer cell proliferation by suppressing mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev Res 3: 1015-1025.
7. Chen W, Tang F, Xie B, Chen S, Huang H, Liu P, (2012). Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress. Eur J Pharmacol 674: 359-364.
8. Cheng X, Zhang DL, Li XB, Ye JT, Shi L, Huang ZS, et al. (2014). Syntheses of diacyltanshinol derivatives and their suppressive effects on macrophage foam cell formation by reducing oxidized LDL uptake. Bioorg Chem 52: 24-30.
9. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, et al. (2000). Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 275: 12633-12638.
10. Don MJ, Liao JF, Lin LY, Chiou WF, (2007). Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway. Br J Pharmacol 151: 638-646.
11. Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S, (2012). Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 220: 3-10.
12. Han JY, Fan JY, Horie Y, Miura S, Cui DH, Ishii H, et al. (2008). Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 117: 280-295.
13. Inoue K, Arai Y, Kurihara H, Kita T, Sawamura T, (2005). Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res 97: 176-184.
14. Jeon SJ, Son KH, Kim YS, Choi YH, Kim HP, (2008). Inhibition of prostaglandin and nitric oxide production in lipopolysaccharide-treated RAW 264.7 cells by tanshinones from the roots of Salvia miltiorrhiza bunge. Arch Pharm Res 31: 758-763.
15. Jin HJ, Li CG, (2013). Tanshinone IIA and cryptotanshinone prevent mitochondrial dysfunction in hypoxia-induced H9c2 cells: association to mitochondrial ROS, intracellular nitric oxide, and calcium levels. Evid Based Complement Alternat Med 2013: 610694.
16. Jin YC, Kim CW, Kim YM, Nizamutdinova IT, Ha YM, Kim HJ, et al. (2009). Cryptotanshinone, a lipophilic compound of Salvia miltiorrhiza root, inhibits TNF-alpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo. Eur J Pharmacol 614: 91-97.
17. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, et al. (1999). Expression of lectin like oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 99: 3110-3117.
18. Kato R, Mori C, Kitazato K, Arata S, Obama T, Mori M, et al. (2009). Transient increase in plasma oxidized LDL during the progression of atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 29: 33-39.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Kim EJ, Jung SN, Son KH, Kim SR, Ha TY, Park MG, et al. (2007). Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Mol Pharmacol 72: 62-72.
21. Kim JA, Territo MC, Wayner E, Carlos TM, Parhami F, Smith CW, et al. (1994). Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL. Arterioscler Thromb 14: 427-433.
22. Krause KH, (2007). Aging: a revisited theory based on free radicals generated by NOX family NADPH oxidases. Exp Gerontol 42: 256-262.
23. Li AC, Glass CK, (2002). The macrophage foam cell as a target for therapeutic intervention. Nat Med 8: 1235-1242.
24. Li D, Mehta JL, (2000a). Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 20: 1116-1122.
25. Li D, Mehta JL, (2000b). Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101: 2889-2895.
26. Li D, Mehta JL, (2009). Intracellular signaling of LOX-1 in endothelial cell apoptosis. Circ Res 104: 566-568.
27. Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL, (2003). LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 107: 612-617.
28. Li DY, Chen HJ, Mehta JL, (2001). Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 52: 130-135.
29. Libby P, (2002). Inflammation in atherosclerosis. Nature 420: 868-874.
30. Libby P, Ridker PM, Hansson GK, (2011). Progress and challenges in translating the biology of atherosclerosis. Nature 473: 317-325.
31. Libby P, Lichtman AH, Hansson GK, (2013). Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38: 1092-1104.
32. Liu Z, Wang J, Huang E, Gao S, Li H, Lu J, et al. (2014). Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. J Lipid Res 55: 201-213.
33. Livak KJ, Schmittgen TD, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
34. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
35. Mehta JL, Chen J, Yu F, Li DY, (2004). Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 64: 243-249.
36. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, et al. (2007). Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 100: 1634-1642.
37. Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, et al. (2009). Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. Neurosci Lett 452: 90-95.
38. Mei Z, Yan P, Situ B, Mou Y, Liu P, (2012). Cryptotanshinone inhibits beta-amyloid aggregation and protects damage from beta-amyloid in SH-SY5Y cells. Neurochem Res 37: 622-628.
39. Mitra S, Goyal T, Mehta JL, (2011). Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 25: 419-429.
40. Moore KJ, Tabas I, (2011). Macrophages in the pathogenesis of atherosclerosis. Cell 145: 341-355.
41. Pan Y, Bi HC, Zhong GP, Chen X, Zuo Z, Zhao LZ, et al. (2008). Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza). Xenobiotica 38: 382-398.
42. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
43. Ramos CL, Huo Y, Jung U, Ghosh S, Manka DR, Sarembock IJ, et al. (1999). Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice. Circ Res 84: 1237-1244.
44. Ross R, (1999). Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
45. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H, (2001). Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104: 1767-1772.
46. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. (1997). An endothelial receptor for oxidized low-density lipoprotein. Nature 386: 73-77.
47. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, et al. (2009). Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 69: 193-202.
48. Suh SJ, Jin UH, Choi HJ, Chang HW, Son JK, Lee SH, et al. (2006). Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. Biochem Pharmacol 72: 1680-1689.
49. Tang F, Wu X, Wang T, Wang P, Li R, Zhang H, et al. (2007). Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascul Pharmacol 46: 427-438.
50. Tang FT, Cao Y, Wang TQ, Wang LJ, Guo J, Zhou XS, et al. (2011a). Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol 650: 275-284.
51. Tang S, Shen XY, Huang HQ, Xu SW, Yu Y, Zhou CH, et al. (2011b). Cryptotanshinone suppressed inflammatory cytokines secretion in RAW264.7 macrophages through inhibition of the NF-kappaB and MAPK signaling pathways. Inflammation 34: 111-118.
52. Tang Y, Chen Y, Chu Z, Yan B, Xu L, (2014). Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 723: 494-500.
53. Wang X, Morris-Natschke SL, Lee KH, (2007). New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 27: 133-148.
54. White SJ, Sala-Newby GB, Newby AC, (2011). Overexpression of scavenger receptor LOX-1 in endothelial cells promotes atherogenesis in the ApoE(-/-) mouse model. Cardiovasc Pathol 20: 369-373.
55. Xu H, Goettsch C, Xia N, Horke S, Morawietz H, Forstermann U, et al. (2008). Differential roles of PKCalpha and PKCepsilon in controlling the gene expression of Nox4 in human endothelial cells. Free Radic Biol Med 44: 1656-1667.
56. Xu S, Liu P, (2013a). Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat 23: 149-153.
57. Xu S, Fu J, Chen J, Xiao P, Lan T, Le K, et al. (2009). Development of an optimized protocol for primary culture of smooth muscle cells from rat thoracic aortas. Cytotechnology 61: 65-72.
58. Xu S, Little PJ, Lan T, Huang Y, Le K, Wu X, et al. (2011). Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys 515: 72-79.
59. Xu S, Liu Z, Huang Y, Le K, Tang F, Huang H, et al. (2012). Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-kappaB activation. Transl Res 160: 114-124.
60. Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P, (2013b). LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci 70: 2859-2872.
61. Xu X, Gao X, Potter BJ, Cao JM, Zhang C, (2007). Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler Thromb Vasc Biol 27: 871-877.
62. Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ, et al. (2013). Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-kappaB-dependent transcriptional activity. Br J Pharmacol 168: 117-128.
63. Zhou Z, Wang SQ, Liu Y, Miao AD, (2006). Cryptotanshinone inhibits endothelin-1 expression and stimulates nitric oxide production in human vascular endothelial cells. Biochim Biophys Acta 1760: 1-9.